I-MAB (FRA:0VY) Other Stockholders Equity : €-0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Other Stockholders Equity?

I-MAB's Other Stockholders Equity for the quarter that ended in Dec. 2023 was €-0.00 Mil.

I-MAB's quarterly Other Stockholders Equity increased from Dec. 2022 (€-0.00 Mil) to Jun. 2023 (€0.00 Mil) but then declined from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€-0.00 Mil).

I-MAB's annual Other Stockholders Equity stayed the same from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€-0.00 Mil) but then declined from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€-0.00 Mil).

I-MAB Other Stockholders Equity Historical Data

The historical data trend for I-MAB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Other Stockholders Equity Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Stockholders Equity	Get a 7-Day Free Trial								-	-	-	-	-

I-MAB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

I-MAB Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of I-MAB's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (FRA:0VY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (FRA:0VY) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

IMAB:USA

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.

I-MAB (FRA:0VY) Headlines

No Headlines